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The role of APRIL and BAFF in lymphocyte activation
Pascal SchneiderThe TNF family ligands BAFF (also called BLyS) and APRIL
regulate lymphocyte survival and activation. BAFF binds to
three receptors, BAFF-R, TACI and BCMA, whereas APRIL
interacts with TACI, BCMA and proteoglycans. The
contribution of BAFF and APRIL to B-cell and plasma-cell
survival, CD154 (CD40L)-independent antibody isotype
switching, germinal center maintenance, T-dependent and
T-independent antibody responses, and T cell co-stimulation
are relatively well understood. Constitutive BAFF produced
by stromal cells determines the size of the peripheral B cell
pool, whereas inducible BAFF produced by myeloid and other
cells supports local survival of B lymphocytes and can be
associated with development of autoimmunity when
deregulated.Addresses
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Introduction
TNF family members are type II transmembrane pro-
teins that spontaneously form homotrimers and are mem-
brane-bound or solubilized ligands for a cognate family of
receptors. APRIL (a proliferation-inducing ligand) and
BAFF (B-cell activation factor of the TNF family; also
called BLyS or TALL-1) were initially identified on the
basis of their homology to TNF, although there were few
clues as to their physiological functions. These ligands,
however, were rapidly implicated in several immunolo-
gical phenomena that previously lacked a satisfactory
molecular explanation, such as peripheral B-cell survival,
CD154 (CD40L)-independent antibody isotype switch-
ing and the induction of self-reactive B cells. Merging
these different fields has proven rather successful and has
provided an increasingly coherent overview of the action
of BAFF and APRIL in the immune system. This knowl-
edge will certainly translate into therapeutic applications
in the near future.Current Opinion in Immunology 2005, 17:282–289This review focuses on structural and functional aspects
of the BAFF–APRIL subfamily, and attempts to describe
the roles played by the many receptors of this subfamily
in the immune function of healthy individuals.
The interactions of BAFF and APRIL with
their receptors and binding partners
Ligand–receptor interactions within the BAFF–APRIL
subfamily of TNF ligands are both redundant and spe-
cific; for example, BAFF binds to BAFF-R, TACI (trans-
membrane activator and CAML interactor) and, with
lower affinity, to BCMA (B-cell maturation antigen),
whereas APRIL binds to TACI and BCMA (Figure 1)
[1,2–5]. In addition, APRIL interacts with proteogly-
cans, which are structurally unrelated to TNF receptors,
and are likely to be the initially unidentified APRIL-
specific binding partner that was predicted to exist several
years ago (K Ingold et al., unpublished; [6]). This inter-
action involves acidic sulfated glycosaminoglycan (GAG)
sidechains of proteoglycans and basic amino acid resi-
dues, which are present in APRIL, but not in BAFF, and
is independent from the interaction site for TACI and
BCMA (K Ingold et al., unpublished; Figure 2).
How does BAFF-R distinguish between BAFF and
APRIL ligands when TACI and BCMA do not, or rather
only incompletely? TNF receptors contain cysteine-rich
domains (CRDs) in their extracellular portion, and struc-
tural studies indicate that BAFF and APRIL receptors
differ from most other TNF receptor family members, as
they have a single CRD that contacts one ligand subunit,
instead of several CRDs that contact the boundary
between two ligand subunits [1,7–9] (Figure 2). TACI
can be classified as a single CRD receptor (although it
contains two CRDs) because the amino-terminal CRD
does not contribute to ligand binding and is absent in a
splice variant encoding a short, functional form of TACI
[1]. BAFF-R, BCMA and TACI all contain a conserved
b hairpin structure followed by a more variable motif.
The variable motif includes a loop in BAFF-R, or a loop-
helix-loop motif in both TACI and BCMA, that adopts
different orientations. The hairpin is alone sufficient for
BAFF binding [1,7,9,10], but binding to APRIL
requires a specific hydrophobic residue in the hairpin
that is found in TACI and BCMA but not in BAFF-R
[1,2]. In addition, the variable motif of BAFF-R is
detrimental for APRIL binding, which explains the
exquisite specificity of BAFF-R for BAFF but not APRIL
[7], whereas the corresponding motifs of TACI and
BCMA promote different interactions with ligands and
are therefore likely to dictate the differential affinity for
BAFF [1,2].www.sciencedirect.com
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Ligand specificity and function assignment of BAFF and APRIL receptors in the immune system. The interactions of BAFF and APRIL with their
receptors (BAFF-R, BCMA and TACI) are shown in the upper part of the figure. The phenotypic and functional outcomes of BAFF and/or APRIL
signaling are listed at the bottom and encircled in color to reflect the involvement of one or more receptors in mediating a particular effect
(BAFF-R, yellow; BCMA, pink; TACI, light blue). The assignment of receptor tasks is tentative, as conflicting data exist for some of these functions.
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Structural basis for the binding of (a) BAFF, (b) APRIL and (c) TRAIL to receptors and interaction partners. Lateral and bottom views of ligand–receptor
complexes are shown (top and bottom panels, respectively). One monomer within each trimeric ligand is shown in red, whereas the receptors
are depicted in green with SS-bridges highlighted in yellow. A heparin fragment (GAG, orange) was manually docked onto the basic residues of
APRIL (shown in blue) that are believed to mediate interaction with glycosaminoglycans (GAGs). Structures for APRIL, BAFF and TRAIL are
based on PDB atomic coordinate files 1XU1, 1OQE and 1DOG, respectively, and heparin is based on file 1FQ9.
www.sciencedirect.com Current Opinion in Immunology 2005, 17:282–289
284 Lymphocyte activationBAFF and APRIL have additional structural features of
uncertain physiological relevance. TWE-PRIL (TWEAK-
APRIL fusion protein) is a fusion protein containing the
TNF homology domain of APRIL fused to the amino-
terminal portion of another TNF family ligand, TWEAK
(TNF-related weak inducer of apoptosis). TWE-PRIL
might represent a membrane-bound form of APRIL [11].
In addition, a splice variant of BAFF (DBAFF) inhibits
regular BAFF by forming inactive heteromers [12]. This
strategy could be exploited to poison endogenous BAFF
with exogenously added recombinant BAFF mutants
[13], and could be used to intervene in autoimmune
and other conditions in which BAFF is produced in
excess. BAFF can also heterotrimerize with APRIL in
undefined stoichiometry [14], although this process
appears to be far less efficient than the heterotrimeriza-
tion of lymphotoxin a1b2, a well-characterized hetero-
trimer of the TNF family. Finally, recombinant soluble
BAFF trimers have a pH-dependent propensity to form
spherical structures composed of 20 trimers, whose spe-
cific signaling properties largely remain to be explored
[7,9,15].
Two pools of BAFF
There are two distinct pools of BAFF in the mouse. A
constitutive pool is produced in fixed amounts by radia-
tion-resistant cells (these are possibly stromal cells from
lymphoid organs) and controls the size of the peripheral B
cell pool [16,17]. In addition, an accessory cytokine-
inducible pool of BAFF is produced locally by cells of
myeloid origin, such as monocytes, macrophages, dendri-
tic cells and neutrophils, other fibroblast-like cells or even
astrocytes. This cytokine-inducible pool enables the tran-
sient accumulation of additional B-cell populations; for
example, at inflammatory sites [16,18–22]. This concept
goes beyond the generally accepted idea that cells of
myeloid origin are the main producers of BAFF. Indeed,
if bone-marrow-derived cells are the main source of
BAFF, lethally irradiated wild-type recipients reconsti-
tuted with BAFF-deficient bone marrow should be phe-
notypically similar to BAFF-deficient mice; however,
experimental data reveal that these mice are normal
[16]. Does this mean that BAFF produced by cells of
myeloid origin plays no role? This is not the case, because
the reverse experiment (wild-type bone marrow trans-
planted into irradiated BAFF-deficient mice) demon-
strates that dendritic cells and macrophages can indeed
produce BAFF and locally sustain B cell survival,
although they are unable to maintain normal B cell counts
and circulating BAFF levels [16].
BAFF and B cell homeostasis
Cells that produce BAFF constitutively are apparently
unaffected by the presence or absence of B cells. If fewer
B cells are present than can be sustained by BAFF, the
circulating pool of BAFF is augmented and reaches its
highest levels in the extreme case of a total B-cellCurrent Opinion in Immunology 2005, 17:282–289deficiency [17]. If, on the contrary, more B cells are
present than can be supported by BAFF, those cells most
dependent on BAFF will die. B-cell survival depends not
only on BAFF-R signals but also on basal signals
mediated by the B-cell receptor (BCR) that might control,
at least in part, BAFF-R expression [23,24]. Despite its
role in B cell survival, if a BCR signal becomes too strong
in transitional peripheral B cells it results in anergy or
toxicity, most probably as a result of the activation of pro-
apoptotic factors such as Bim [17]. Autoreactive B cells,
which have their BCR engaged by self-antigens, might be
particularly prone to this type of death induction and
require proportionally stronger survival signals than reg-
ular cells to escape death. If BAFF is limited, autoreactive
B cells die. But if autoreactive B cells are exposed to
sufficient BAFF supply, either because they are the only
ones present in the experimental system, or because
BAFF is produced in excess from a transgene or from
hyperactivated dendritic cells (such as those displaying
complete deficiency for suppressor of cytokine signaling-
1 [SOCS-1]), they will survive and be allowed to reach
locations such as the B cell follicle or splenic marginal
zone where they are more likely to encounter microor-
ganism-derived polyclonal activators that will precipitate
their activation [17,25,26]. Similar mechanisms might
be at work in patients with chronic inflammatory auto-
immune diseases.
BAFF-independent B-cell survival
It might be beneficial for essential B cell populations to
become independent of BAFF signals in order to prevent
their accidental disappearance. The observation that
human plasmablasts express both BCMA and BAFF-R
and survive in response to both BAFF and APRIL
(Table 1; [27]), together with the observation that the
survival of long-lived murine bone marrow plasma cells
depends on BCMA (Table 2; [28]), suggests that some
cells may indeed partially shortcut the need for BAFF by
complementing or replacing the BAFF–BAFF-R system
with an APRIL–BCMA survival axis. APRIL recruitment
to these cells might be facilitated by the expression of
syndecan-1 (also called CD138), a proteoglycan that
interacts with APRIL (K Ingold et al., unpublished).
This regulatory system can be circumvented by some
lymphoid malignancies that develop an advantage by
producing their own BAFF and/or APRIL supply [29–
31]. Memory B cells might even survive independently of
BAFF and APRIL. Mice immunized with a T-dependent
antigen and subsequently administered adenovirus-
encoded soluble TACI-Ig (a fusion protein comprising
TACI and immunoglobulin acting as BAFF and APRIL
inhibitor) displayed pronounced decreases in peripheral
B cell and extrafollicular IgM-producing plasma cell
numbers, but remained competent for mounting an effi-
cient recall response to the immunizing antigen after
termination of the TACI-Ig treatment. This suggests thatwww.sciencedirect.com
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Table 1
Cellular distribution of receptor expression (protein level).
Human Mouse
Cell type hBAFF-R hTACI hBCMA Cell type mBAFF-R mTACI
Splenic B cells +++ [27] No [27] No [27] T1 B cells ++ [35] No [35,39]
Tonsil B cells (non-GC) +++ [39] + [39] No [39] T2 B cells +++ [35] ++ [39] + [35]
GC tonsil B cells ++ [39] No [39] + [39] Marginal zone B cells ND ++ [39]
Blood B cells +++ [30,39,54] + (subset)
[30,39,54]
No [30,39,54]
+ (HIV) [54]
Follicular B cells +++ [35] + (++ with anti-m)
[35,39]
Blood memory
(CD27+) B cells
+++ [30] + [30] No [30] Blood B cells +++ [39] ND
Peripheral B1 B cells +++ [30] + [30] No [30] Peritoneal B1 B cells +++ [35] ++ [35]
Plasma cell + [27] No [27] + [27]
Blood T cells + (subset of CD4+) [39]
+ (allograft infiltrating
CD3+ cells) [53]
No [39] No [39] Splenic T cells + (subset of CD4+
Most CD4+ CD25+)
[39,53]
ND
The left- and right-hand sides of the table show expression at the protein level for human and mouse receptors, respectively. Most data
were obtained by FACS analysis using specific antibodies. There is presently no data available regarding the expression of mouse BCMA.
No indicates undetectable expression, +, ++ and +++ indicate the presence of increasing amounts of the receptors. Abbreviations: GC,
germinal center; ND, not determined.memory B cells require either no or only minimal
amounts of BAFF and APRIL for their survival [32].
Task assignment within the BAFF–APRIL
subfamily
B cell survival
B-cell development and selection in the bone marrow is
independent of BAFF [33,34]. Only when B cells exit theTable 2
Phenotype of null mice in the BAFF–APRIL subfamily.
BAFF null APRIL null BAFF-R
Peripheral B cell
subsets
Impaired +++ [35] Normal [45,55] Impaired
[35,40]d
Serum antibody
titers and isotype
switching
Reduced
antibody titers
(except IgA) [33]
Reduced IgA titer [45]
(not always seen [55])
Reduced
titers (ex
[40]
Plasma cell survival
CD21 expression Impaired +++ [36] Impaired
CD23 expression Impaired +++ [36] Impaired
Germinal centersa Impaired ++ no
secondary
FDC reticulum [42]
Increased
number [45]
Impaired
Normal
mLN GC
Marginal zone
B cells
Normal
proportion [36]b
Normal [55] Impaired
TI-II responses Impaired ++ (IgM
and IgG) [33,34]
Normal [45,55] Normal
Impaired
TD responses Impaired ++ (IgM
and IgG) [33,34]
Normal [55] Impaired
IgA to mucosal TD
antigen [45]
Normal
impaired
Impaired
B1 B cells Normal [33,34] Normal [45] (increased
in transgenics) [46]
Normal
aGerminal centers are induced at a normal density in response to immuniz
CD23 expression in BAFF null complicates identification of marginal zone
impaired switching to IgA, IgG1 and IgE in response to APRIL, and to IgA
BAFFR null and BAFFR x TACI double null mice. Peripheral B cells are no
germinal center; LN, lymph node; mLN, mesenteric LN; PP, Peyer’s patch
www.sciencedirect.combone marrow do they become responsive to BAFF survi-
val signals, more precisely as they progress from transi-
tional T1 to transitional T2 stages in the spleen. Survival
requires BAFF and BAFF-R, as deletion of either of these
genes results in an identical, significant reduction of
peripheral B cells that have developed beyond the T1
B cell stage [35]. BAFF is, however, not actively impli-
cated in B cell differentiation at this point because B cellsnull BAFF-R mutant
(A/WySnJ)
TACI null BCMA null
+++ Impaired ++ [56] Increased [44,57]d Normal [58]d
antibody
cept IgA).
Switching to IgA
and IgG occurs [50]
Reduced IgA titer
[44] Impaired
switching to
IgA [45]c
Normal [50,58]
Impaired [28]
+ [40] Impaired + [33,56] Normal [44] Normal [33,58]
+ [35,40] Normal [33,56] Normal [44] Normal [33,58]
+ [35]
in PP and
s [40]
Impaired + No
Ki67 in B cells [42]
+++ [40] Normal
proportion [56]
Normal proportion
[44,57]
Normal [58]
[35]
+ [40]
Normal [59] Impaired ++ [44] Normal [58]
or slightly
IgM [35,40]
IgG [35,40]
Normal IgM
Impaired IgG [59]
Enhanced [44,57] Normal [58]
[35,40] Normal [60] Normal (no
gross loss) [44]
Normal [58]
ation, but exhibit more rapid loss with time. bLoss of CD21 and
B cells in these mice. cNaı¨ve B cells from TACI null mice have
in response to BAFF [50]. dLoss of peripheral B cells is identical in
t lost in TACI x BCMA double null mice [35]. Abbreviations: GC,
.
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286 Lymphocyte activationcan still progress to the mature stage, and antibodies of
various isotypes are made in the absence of BAFF,
although only few B cells reach the mature stage under
these conditions [36]. Consistent with a ‘passive’ survival
role for BAFF, B cells expressing a phospholipase C
(PLC)-g2 mutant enzyme that affects BCR signaling fail
to reach the mature stage despite a functional BAFF
survival pathway [37]. In addition, the co-stimulatory
effects of BAFF on BCR-stimulated cells are a result
of increased survival rather than stimulated cell cycling,
whereas CD154 promotes both survival and cycling under
identical conditions [24]. The survival action of BAFF is
negatively regulated by TACI [38] and, as TACI is
expressed on T2 B cells [35,39], it might fine-tune
the survival function of BAFF–BAFF-R at this stage.
Marginal zone B cell formation also appears to be exqui-
sitely dependent on BAFF-R-mediated signals [40,41].
Surface markers and germinal centers
In addition to their B cell and plasma cell survival
activities, BAFF and APRIL support several other func-
tions. Expression of CD21 and CD23, which are markers
often used to classify B cell populations, is controlled by
BAFF, in part through BAFF-R and in part through
BCMA and/or TACI or via indirect mechanisms
[36,40]. Germinal centers can form in BAFF-null,
BAFF-R-null and BAFF-R mutant (A/WySnJ) mice,
but they are not maintained [35,42,43]. The defect is
more severe in BAFF-null than in A/WySnJ mice, and is
apparently mechanistically different. Germinal centers in
BAFF-null mice do not build a secondary follicular den-
dritic cell (FDC) network and do not trap antigen, suggest-
ing that BAFF affects the FDC network either directly or
indirectly (e.g. via lymphotoxin b). In BAFF-R-null mice,
however, FDC networks are present but B cells fail to
proliferate, possibly because TACI and/or BCMA signals,
in the absence of BAFF-R, prevent cell cycle progression
[42]. In this respect, it is interesting to note that human
germinal center B cells express BCMA [39].
Humoral responses and immunoglobulin switch
BAFF-null and BAFF-R-null mice mount poor but
detectable T-dependent antibody responses, which
might directly reflect the paucity and reduced survival
of peripheral B cells in these mice [33,35,40]. The
situation is quite different for T-independent type II
antibody responses, which require TACI and its ligands,
but for which BAFF-R is dispensable [33,35,44,45]. Gut-
associated B cells are derived from B1 B cells and,
although they do not require BAFF for survival, they
express both BAFF-R and TACI and they give rise to B
cell neoplasms in APRIL transgenic mice [35,46]. In
addition, and in contrast to what is observed in the spleen
of BAFF-R-null mice, the Peyer’s patches and mesen-
teric lymph nodes develop normal germinal centers in
response to gut microflora, which might explain why IgA
serum levels remain normal in BAFF-R-null mice [40].Current Opinion in Immunology 2005, 17:282–289BAFF and/or APRIL might also increase T-independent
antibody responses by prolonging the survival of plasma-
blasts derived from B1 B cells and marginal zone B cells
[47]. Antibody class switching, which occurs in B cells,
requires cytokines and, in the case of T-dependent anti-
gens, CD154. CD154-independent class-switch recombi-
nation does, however, occur in a BAFF- and APRIL-
dependent manner that might be particularly relevant
for the production of IgA, as one particular strain of
APRIL-null mice displays a selective IgA deficiency
and decreased IgA responses to mucosal T-dependent
antigens [45,48,49]. BAFF and APRIL induce isotype
switching to IgG1 and IgA and, with the help of IL-4, to
IgE [50]. Interestingly, both BAFF-R and TACI are able
to signal isotype switching to IgG1 and IgE, but the switch
to IgA is controlled by TACI only [50]. Isotype switching
controlled by APRIL and BAFF might be achieved, in
part, via the induction of IL-10 [50].
T cell co-stimulation
In addition to regulating multiple B-cell related func-
tions, BAFF is increasingly recognized as an important co-
stimulator of T-cell function. Human T cells respond to
recombinant or endogenous BAFF by secreting IFN-g
and IL-2, upregulating CD25 (IL-2 receptor a chain) and
proliferating in an IL-2-dependent manner [51,52].
BAFF-R is expressed on only a few percent of human
and murine T cells, is upregulated upon T cell activation
[39,53], and is expressed by most murine CD4+ CD25+
regulatory T cells [53]. BAFF induces BAFF-R-depen-
dent Bcl-2 expression in T cells and might therefore help
survival [39]. Functionally, blockade of BAFF or BAFF-
R prevents T-cell mediated allograft heart rejection in the
mouse, in synergy with low doses of the immunosuppres-
sive drug cyclosporine A [53]. Validated antibodies failed
to detect TACI expression on T cells, and T-cell respon-
siveness was impaired only in BAFF- and BAFF-R-defi-
cient, but not in TACI-deficient animals, strongly
implicating BAFF-R as the only receptor that mediates
BAFF responses in T cells [39,53].
Concluding remarks
BAFF is a primordial B-cell survival factor that also has
additional roles, including T-cell activation; the contribu-
tion of APRIL to plasma cell survival, isotype switching
and T-independent antibody responses is now relatively
well established. Studies published during the past two
years have unveiled the roles played by these different
receptors, but much remains to be understood concerning
the contribution of BAFF and APRIL signaling pathways
in mediating these pleiotropic effects. The expression of
selected mutant receptors in receptor-deficient mice is
one of several approaches that will broaden our compre-
hension of the relative importance of these signaling
pathways. Considerable efforts have been undertaken
to define the function of BAFF and APRIL, and to
develop agonists and antagonists of this system that willwww.sciencedirect.com
APRIL and BAFF in lymphocyte activation Schneider 287hopefully provide new drugs in the future for autoim-
mune conditions such as systemic lupus erythematosus
and rheumatoid arthritis.
Update
The work referred to in the text as (K Ingold et al.,
unpublished) is now in press [61].
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